Noteworthy Price Action: Is Buying Stock Like Jazz Pharmaceuticals plc – Ordinary Shares After Such Increase Winning Strategy?

Noteworthy Price Action: Is Buying Stock Like Jazz Pharmaceuticals plc   Ordinary Shares After Such Increase Winning Strategy?

The stock of Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ) is a huge mover today! About 742,368 shares traded hands or 34.97% up from the average. Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ) has declined 28.63% since April 4, 2016 and is downtrending. It has underperformed by 29.72% the S&P500.
The move comes after 8 months positive chart setup for the $5.86 billion company. It was reported on Nov, 4 by Barchart.com. We have $159.14 PT which if reached, will make NASDAQ:JAZZ worth $3.11 billion more.

Analysts await Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ) to report earnings on November, 14. They expect $1.81 EPS, up 30.22% or $0.42 from last year’s $1.39 per share. JAZZ’s profit will be $101.98 million for 14.37 P/E if the $1.81 EPS becomes a reality. After $1.80 actual EPS reported by Jazz Pharmaceuticals plc – Ordinary Shares for the previous quarter, Wall Street now forecasts 0.56% EPS growth.

Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ) Ratings Coverage

Out of 13 analysts covering Jazz Pharmaceuticals (NASDAQ:JAZZ), 11 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 85% are positive. Jazz Pharmaceuticals has been the topic of 20 analyst reports since August 3, 2015 according to StockzIntelligence Inc. Bernstein initiated the shares of JAZZ in a report on Wednesday, November 25 with “Market Perform” rating. The company was maintained on Thursday, August 11 by Deutsche Bank. The rating was initiated by Wells Fargo with “Outperform” on Friday, February 19. The company was maintained on Wednesday, February 24 by Stifel Nicolaus. The stock has “Neutral” rating given by Mizuho on Tuesday, November 10. Mizuho initiated the shares of JAZZ in a report on Friday, October 9 with “Buy” rating. The firm has “Buy” rating given on Monday, April 25 by SunTrust. The rating was maintained by UBS with “Buy” on Wednesday, May 11. SunTrust maintained the stock with “Buy” rating in Thursday, June 2 report. As per Monday, June 6, the company rating was initiated by Goldman Sachs.

According to Zacks Investment Research, “Jazz Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on identifying, developing and commercializing innovative products to meet unmet medical needs in neurology and psychiatry. Company’s goal is to build a broad portfolio of products through a combination of internal development and acquisition/in-licensing activities and to utilize our specialty sales force to promote products in our target markets. They apply novel formulations and drug delivery technologies to known drug compounds, and compounds with the same mechanism of action or similar chemical structure as marketed products, to improve patient care by improving efficacy, reducing adverse side effects or increasing patient compliance relative to existing therapies. Based in Palo Alto, California, the company is committed to working closely with patients, patient advocacy groups and healthcare professionals.”

Insitutional Activity: The institutional sentiment increased to 1.25 in 2016 Q2. Its up 0.26, from 0.99 in 2016Q1. The ratio improved, as 43 funds sold all Jazz Pharmaceuticals plc – Ordinary Shares shares owned while 102 reduced positions. 61 funds bought stakes while 120 increased positions. They now own 52.76 million shares or 1.80% less from 53.73 million shares in 2016Q1.
Counselors holds 0.01% or 1,671 shares in its portfolio. Tekla Mngmt Ltd Liability Co holds 0.9% of its portfolio in Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ) for 156,451 shares. Balyasny Asset Mgmt Ltd Limited Liability Company holds 0.12% of its portfolio in Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ) for 126,190 shares. Regions reported 5,495 shares or 0.01% of all its holdings. Smithfield last reported 62 shares in the company. Bluemountain Mngmt Lc has 5,599 shares for 0.02% of their US portfolio. Credit Suisse Ag, a Switzerland-based fund reported 225,315 shares. The Missouri-based Service Corp has invested 0% in Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ). Winslow Evans & Crocker Inc reported 106 shares or 0% of all its holdings. Bnp Paribas Arbitrage Sa has 5,924 shares for 0% of their US portfolio. Alyeska Inv Gp L P accumulated 352,399 shares or 0.51% of the stock. Shaker Limited Liability Corp Oh reported 2,000 shares or 0.26% of all its holdings. Oxford Asset has 0.42% invested in the company for 71,166 shares. Deutsche Financial Bank Ag has invested 0.04% of its portfolio in Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ). Palisade Capital Mgmt Limited Liability Company Nj reported 1,735 shares or 0.01% of all its holdings.

Insider Transactions: Since May 16, 2016, the stock had 3 buys, and 19 insider sales for $9.29 million net activity. The insider Smith Karen L. bought $83,305. $86,373 worth of Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ) was sold by BERNS PAUL L on Monday, August 15. 200 shares were sold by MILLER MICHAEL PATRICK, worth $23,632. $177,609 worth of shares were sold by Treacy Paul on Tuesday, August 16. On Monday, August 15 the insider Sohn Catherine A. sold $86,373. $86,373 worth of Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ) shares were sold by Winningham Rick E. Mulligan Seamus sold 27,968 shares worth $4.20M.

JAZZ Company Profile

Jazz Pharmaceuticals Public Limited Company, incorporated on March 15, 2005, is a biopharmaceutical company. The Firm is focused on developing and commercializing products that address unmet medical needs. The Firm has a diverse portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. The Company’s lead marketed products include Xyrem (sodium oxybate oral solution) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; Erwinaze for the treatment of acute lymphoblastic leukemia (ALL), and Defitelio (defibrotide) for the treatment of severe hepatic veno-occlusive disease (VOD). The Company’s other product candidates include JZP-110 for treatment of excessive daytime sleepiness (EDS) in narcolepsy and EDS in patients with obstructive sleep apnea (OSA) and JZP-386 for the treatment of EDS in narcolepsy.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags:

Related posts

Leave a Comment